Xencor Inc (XNCR)
Xencor Inc (XNCR)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total | NaN | 125,576 | NaN | NaN |
| External research and development expense-Xm Ab819ENPP3XCD3 | NaN | 23,119 | NaN | NaN |
| External research and development expense-Xm Ab657CD19XCD3 | NaN | 13,767 | NaN | NaN |
| External research and development expense-Xm Ab942Xtend TL1A | NaN | 13,419 | NaN | NaN |
| External research and development expense-Xm Ab541CLDN6XCD3 | NaN | 12,742 | NaN | NaN |
| External research and development expense-Xm Ab412TL1AXIL23p19 | NaN | 8,064 | NaN | NaN |
| External research and development expense-Plamotamab CD20XCD3 | NaN | 7,229 | NaN | NaN |
| External research and development expense-Xm Ab808B7H3XCD28 | NaN | 5,888 | NaN | NaN |
| External research and development expense-Other Programs Including Research And Early Stage | NaN | 18,229 | NaN | NaN |
| External research and development expense-Wind Down Costs Of Terminated Programs | NaN | 17,224 | NaN | NaN |
| Internal research and development expenses | NaN | 94,783 | NaN | NaN |
| Research and development stock based compensation | NaN | 24,970 | NaN | NaN |
| General and administrative | NaN | 63,644 | NaN | NaN |
| Other income (expense), net | NaN | 87,869 | NaN | NaN |
| Accounts receivable | NaN | NaN | -19,896 | -14,636 |
| Income tax expense | NaN | 2,504 | NaN | NaN |
| Net loss | -128,916 | -6,653 | -6,027 | -79,457 |
| Depreciation and amortization | 2,567 | 2,577 | 2,589 | 5,346 |
| Accretion of discount on marketable debt securities, net | 128 | 340 | 1,652 | 1,489 |
| Stock-based compensation | 9,561 | 10,185 | 10,092 | 22,950 |
| Gain on sale of marketable securities, net | NaN | 9,415 | -407 | 5,380 |
| Change in fair value of marketable equity securities | -51,929 | 41,990 | 44,608 | 528 |
| Asset impairment charges | 0 | 881 | 1,565 | 6,723 |
| Non-cash royalty revenue related to the sale of future royalties | 4,416 | 22,438 | 20,997 | 36,831 |
| Non-cash interest expense on liabilities related to the sale of future royalties | 4,700 | 7,352 | 7,663 | 16,906 |
| Equity received in connection with license agreement | NaN | 0 | NaN | NaN |
| Abandonment of capitalized intangibles | NaN | 0 | NaN | NaN |
| Loss on disposal of assets | NaN | 0 | NaN | NaN |
| Accounts receivable | -5,800 | -28,734 | NaN | NaN |
| Interest receivable from marketable debt securities | NaN | -2,622 | NaN | NaN |
| Prepaid expenses and other assets | 2,165 | -680 | -5,257 | -3,504 |
| Accounts payable | -2,871 | 1,691 | -9,454 | 3,810 |
| Accrued expenses | -707 | 6,942 | 4,223 | 2,631 |
| Income taxes | NaN | 3,589 | NaN | NaN |
| Operating lease, net | -590 | -490 | 13 | 877 |
| Deferred revenue | NaN | 0 | NaN | NaN |
| Other assets and liabilities, net | 2,392 | 1,106 | -216 | 6,287 |
| Net cash used in operating activities | -67,628 | -51,711 | -30,817 | -52,589 |
| Purchase of marketable debt securities | 72,679 | 37,850 | 84,235 | 176,810 |
| Purchase of property and equipment | 610 | 1,140 | 183 | 1,827 |
| Purchase of patents | NaN | 0 | 0 | 0 |
| Proceeds from issuance of common stock under the employee stock purchase plan | NaN | 628 | 0 | 662 |
| Proceeds from sales of marketable equity securities | NaN | 23,163 | 379 | 13,399 |
| Proceeds from issuance of common stock and pre-funded warrants | NaN | 0 | 0 | NaN |
| Proceeds from maturities of marketable debt securities | 99,966 | 87,000 | 98,707 | 219,382 |
| Common stock and pre-funded warrants issuance costs | NaN | 0 | 0 | NaN |
| Proceeds from sale of property and equipment | NaN | 0 | NaN | NaN |
| Proceeds from the sale of future royalties | NaN | 0 | NaN | NaN |
| Net cash provided by investing activities | 26,677 | 71,173 | 14,668 | 54,144 |
| Proceeds from noncontrolling interest | NaN | 0 | NaN | NaN |
| Proceeds from the exercises of stock options | 950 | 5,693 | 0 | 2,974 |
| Cash paid to acquire noncontrolling interest | 0 | 0 | 0 | 1,725 |
| Net cash provided by financing activities | 950 | 6,321 | 0 | 1,911 |
| Net decrease in cash, cash equivalents, and restricted cash | -40,001 | 25,783 | -16,149 | 3,466 |
| Cash, cash equivalents, and restricted cash, beginning of period | 54,362 | 28,579 | 41,262 | NaN |
| Cash, cash equivalents, and restricted cash, end of period | 14,361 | 54,362 | 28,579 | NaN |